Expert Review of Cardiovascular Therapy最新文献_第5页

Response to letter to the editor: 'Advances in biomarker discovery for peripartum cardiomyopathy: current status and future directions'. 回复给编辑的信：“围产期心肌病生物标志物发现的进展：现状和未来方向”。

IF 2.5

Expert Review of Cardiovascular Therapy Pub Date : 2026-06-01 Epub Date: 2026-06-02 DOI: 10.1080/14779072.2026.2682169

Elsa Pretorius, Shreya Reddy Annareddy Venkata Sai, Aniyah Barnet, Vitaris Kodogo, Karen Sliwa, Graham Chakafana, Tawanda Zininga

引用次数: 0

Letter to the editor: 'Advances in biomarker discovery for peripartum cardiomyopathy: current status and future directions'. 致编辑的信：“围产期心肌病生物标志物发现的进展：现状和未来方向”。

IF 2.5

Expert Review of Cardiovascular Therapy Pub Date : 2026-06-01 Epub Date: 2026-05-29 DOI: 10.1080/14779072.2026.2682165

Jakob Triebel

引用次数: 0

Permanent pacemakers in pediatric patients: novel and emerging technologies. 儿科患者的永久起搏器：新技术和新兴技术。

IF 2.5

Expert Review of Cardiovascular Therapy Pub Date : 2026-06-01 Epub Date: 2026-06-08 DOI: 10.1080/14779072.2026.2686149

Tobias Donlon, Erick Jimenez, Bradley C Clark

{"title":"Permanent pacemakers in pediatric patients: novel and emerging technologies.","authors":"Tobias Donlon, Erick Jimenez, Bradley C Clark","doi":"10.1080/14779072.2026.2686149","DOIUrl":"10.1080/14779072.2026.2686149","url":null,"abstract":"Introduction: Though cardiac pacing has evolved substantially since its introduction, continued advancement is necessary to meet the needs of small patients and those with congenital heart disease.Areas covered: This narrative review summarizes current and emerging technologies for pediatric pacing based on a comprehensive search via PubMed and Google Scholar of peer-reviewed literature through April 2026. Technologies discussed include leadless pacemakers, pediatric-specific pulse generators for neonates, minimally invasive epicardial access techniques, and alternative pacing strategies for those with abnormal systemic venous anatomy. Additional areas of investigation include novel battery technologies such as energy harvesting, wireless power transfer, and experimental approaches to fetal pacing.Expert opinion: Although modern pacing systems have improved substantially over recent decades, current technologies do not meet the needs of many pediatric patients. Continued innovation in lead design, power sources, and minimally invasive implantation will be necessary to improve durability, reduce procedural burden and device-related morbidity, and expand pacing options for children with congenital and acquired conduction system disease. Given the relative rarity of conduction system disease in pediatric populations, multicenter collaboration is essential to support continued development of pediatric-specific technologies.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"521-531"},"PeriodicalIF":2.5,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148162311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Leadless pacing comes of age: what the new NICE guidance means for UK practice. 无引线节奏的到来：新的NICE指南对英国实践意味着什么。

IF 2.5

Expert Review of Cardiovascular Therapy Pub Date : 2026-06-01 Epub Date: 2026-06-11 DOI: 10.1080/14779072.2026.2686148

Tom Wong

引用次数: 0

Compliance with the ABC pathway for integrated care of patients with atrial fibrillation in Brazil: a retrospective cohort study. 依从ABC途径对巴西房颤患者的综合护理：一项回顾性队列研究。

IF 2.5

Expert Review of Cardiovascular Therapy Pub Date : 2026-06-01 Epub Date: 2026-06-16 DOI: 10.1080/14779072.2026.2686161

Itamar S Santos, Alessandra C Goulart, Rodrigo D Olmos, Ana C Varella, Carla R Quintino, Otávio C E Gebara, Ana T A Lopes, Flavia P P L Lopes, Tiffany E Gooden, G Neil Thomas, Gregory Y H Lip, Paulo A Lotufo, Isabela M Benseñor

{"title":"Compliance with the ABC pathway for integrated care of patients with atrial fibrillation in Brazil: a retrospective cohort study.","authors":"Itamar S Santos, Alessandra C Goulart, Rodrigo D Olmos, Ana C Varella, Carla R Quintino, Otávio C E Gebara, Ana T A Lopes, Flavia P P L Lopes, Tiffany E Gooden, G Neil Thomas, Gregory Y H Lip, Paulo A Lotufo, Isabela M Benseñor","doi":"10.1080/14779072.2026.2686161","DOIUrl":"10.1080/14779072.2026.2686161","url":null,"abstract":"Background: Information about integrated care for patients with atrial fibrillation (AF) in low- and middle-income countries is scarce.Methods: We analyzed multicentre data from 699 patients with AF treated in São Paulo, Brazil. ABC compliance was defined as (1) adequate anticoagulation ('A' component); (2) controlled AF symptoms ('B' component); and (3) comorbidities treatment ('C' component). We built logistic regression models to identify characteristics associated with ABC compliance.Results: Mean age was 69.4 ± 14.4 years (45.8% women; 57.4% from private healthcare). Compliance with ABC pathway, and with the 'A,' 'B' and 'C' components occurred in 20.9%, 42.3%, 81.7% and 50.1% of the participants, respectively. Lack of ABC compliance was associated with female sex (adjusted odds ratio [aOR]: 1.66; p = 0.015), intermediate (aOR: 3.37; p < 0.001) and high (aOR: 9.17; p < 0.001) bleeding risk. Patients with AF treated in public units had worse performance for the 'A' component (aOR: 2.50; p < 0.001) and better performance for the 'C' component (aOR: 0.49; p < 0.001) compared to those using private healthcare.Conclusions: Compliance with the ABC pathway in São Paulo, Brazil was low. Lack of ABC compliance was more common in women and individuals with high bleeding risk. We found a mixed pattern of ABC compliance in public and private units.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"549-558"},"PeriodicalIF":2.5,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148204478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeted screening for heart failure in primary care: evidence, challenges and a pathway-first approach to implementation. 在初级保健中有针对性地筛查心力衰竭：证据、挑战和途径优先的实施方法。

IF 2.5

Expert Review of Cardiovascular Therapy Pub Date : 2026-06-01 DOI: 10.1080/14779072.2026.2675469

Saloni Nakhare, Mihir A Kelshiker, Holly Young, Federica Re, Karanjot Chhatwal, Mona Jaffar-Karballai, Camille F Petri, Rakesh Velmurugan, Anastasija Schmidt, Nicholas S Peters, Patrik Bächtiger

{"title":"Targeted screening for heart failure in primary care: evidence, challenges and a pathway-first approach to implementation.","authors":"Saloni Nakhare, Mihir A Kelshiker, Holly Young, Federica Re, Karanjot Chhatwal, Mona Jaffar-Karballai, Camille F Petri, Rakesh Velmurugan, Anastasija Schmidt, Nicholas S Peters, Patrik Bächtiger","doi":"10.1080/14779072.2026.2675469","DOIUrl":"10.1080/14779072.2026.2675469","url":null,"abstract":"Introduction: Heart failure remains a leading cause of morbidity and mortality, yet diagnosis continues to occur late in routine practice, frequently during emergency hospitalization. Primary care is well positioned to detect heart failure earlier, but indiscriminate screening approaches have not delivered timely diagnosis at scale. This has prompted growing interest in targeted screening strategies while raising important practical implementation challenges.Areas covered: This Special Report synthesizes the evidence and operational pathways underpinning screening for heart failure in primary care. Heart failure is a heterogeneous umbrella diagnosis, with important implications for how screening pathways are designed and scaled across its subtypes. Evidence from existing screening pathways and implementation studies is considered, from established biomarkers to newer diagnostic approaches, including machine learning-enabled tools and risk prediction models. A systematic search of PubMedMEDLINE, EMBASE, and the Cochrane Library was conducted using key terms including 'heart failure,' 'screening,' 'primary care,' and 'artificial intelligence,' encompassing publications up to January 2026.Expert opinion: Implementation of any innovative technology in healthcare relies on effective pathway redesign as the primary determinant of impact. Progress will depend on targeted, risk-based screening pathways evaluated through pragmatic, implementation-aware trials to determine whether screening improves outcomes, for whom, and under what conditions.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"513-520"},"PeriodicalIF":2.5,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148028728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An interview with Prof. Tom Wong on leadless pacing and NICE guidance in the UK - by Reegan Burnell-Clarke (commissioning editor). 作者：Reegan Burnell-Clarke（委托编辑）对Tom Wong教授关于英国无引线节奏和NICE指导的采访。

IF 2.5

Expert Review of Cardiovascular Therapy Pub Date : 2026-06-01 Epub Date: 2026-06-24 DOI: 10.1080/14779072.2026.2686549

Tom Wong

引用次数: 0

Time for a new category: "acute-on-chronic" hypertensive target organ damage. 是时候提出一个新的分类了：“急性-慢性”高血压靶器官损伤。

IF 2.5

Expert Review of Cardiovascular Therapy Pub Date : 2026-04-01 Epub Date: 2026-04-30 DOI: 10.1080/14779072.2026.2665196

Goran Koraćević, Milovan Stojanovic, Dragan Simic, Miloje Tomasevic, Dragan Lovic, Suzana Otasevic, Predrag Cvetković, Sonja Jankovic

{"title":"Time for a new category: \"acute-on-chronic\" hypertensive target organ damage.","authors":"Goran Koraćević, Milovan Stojanovic, Dragan Simic, Miloje Tomasevic, Dragan Lovic, Suzana Otasevic, Predrag Cvetković, Sonja Jankovic","doi":"10.1080/14779072.2026.2665196","DOIUrl":"10.1080/14779072.2026.2665196","url":null,"abstract":"Introduction: The aims of this paper are as follows: 1) To analyze the evolution of understanding of hypertensive target organ damages (TODs); 2) To see if the concept of 'acute-on-chronic TOD' is commented so far and to provide rationale for its use.Areas covered: Need for the division of hypertensive TODs into acute and chronic is already recognized. Now we propose another subgroup of TODs: 'acute-on-chronic' TODs. The episodes of very high blood pressure are the situations when 'acute-on-chronic TOD' can be expected. The benefit of this category of hypertensive TODs is primary in the clinical setting - enhanced awareness of the possibility of 'acute-on-chronic' TOD may improve our diagnostic decisions.Expert opinion: In the next period of five years, hypertensive TODs are to be classified (as acute, chronic and 'acute-on-chronic') in guidelines on HTN. Additionally, a more precise listing of entities will be agreed upon. Following the analysis of existing and forthcoming studies and registries, with a little help of artificial intelligence, we may obtain a valuable basis to predict future acute hypertensive TODs. Together with improved recognition of acute TODs, it may result in saving of numerous lives worldwide.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"439-448"},"PeriodicalIF":2.5,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147766637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hormone deficiency and cardiovascular disease: clinical impact, treatment strategies and prognostic prediction. 激素缺乏与心血管疾病：临床影响、治疗策略和预后预测。

IF 2.5

Expert Review of Cardiovascular Therapy Pub Date : 2026-04-01 Epub Date: 2026-04-16 DOI: 10.1080/14779072.2026.2649164

Pedro Iglesias

{"title":"Hormone deficiency and cardiovascular disease: clinical impact, treatment strategies and prognostic prediction.","authors":"Pedro Iglesias","doi":"10.1080/14779072.2026.2649164","DOIUrl":"10.1080/14779072.2026.2649164","url":null,"abstract":"Introduction: Hormone deficiency states are increasingly recognized as important, yet often underappreciated, contributors to cardiovascular (CV) disease. Deficits affecting pituitary, thyroid, parathyroid, adrenal, and gonadal axes influence myocardial function, vascular biology, and metabolic homeostasis, leading to increased cardiovascular morbidity and mortality.Areas covered: This narrative review summarizes current evidence on the CV impact of major hormonal deficiencies, including hypopituitarism, growth hormone deficiency, hypoprolactinemia, hypothyroidism, hypoparathyroidism, adrenal insufficiency, and hypogonadism. Hormone-specific CV phenotypes, underlying pathophysiological mechanisms, effects of replacement therapies, residual cardiovascular risk, and prognostic markers are discussed. The literature search was conducted in PubMed/MEDLINE and included studies published between January 2000 and December 2025, with emphasis on systematic reviews, meta-analyses, large observational cohorts, and key clinical trials.Expert opinion: Despite advances in hormone replacement, many patients retain excess CV risk that is not captured by conventional prediction models. Endocrine-adapted risk stratification, individualized replacement strategies considering dose and chronobiology, and integration of emerging tools such as artificial intelligence - based models may improve risk prediction. Dedicated cardiovascular outcome trials in endocrine populations remain a major unmet need.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"323-338"},"PeriodicalIF":2.5,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147572977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Biodegradable devices for transcatheter patent foramen ovale closure: current evidence and future directions. 经导管闭合卵圆孔未闭的可生物降解装置：目前的证据和未来的方向。

IF 2.1

Expert Review of Cardiovascular Therapy Pub Date : 2026-04-01 Epub Date: 2026-04-18 DOI: 10.1080/14779072.2026.2650529

Allahdad Khan, Mishaim Khan, Harshith Thyagaturu, Nimra Shafi, Fnu Muhibullah, Kainat Kanwal, Khuram Irshad, Gregg C Fonarow, Yasar Sattar

{"title":"Biodegradable devices for transcatheter patent foramen ovale closure: current evidence and future directions.","authors":"Allahdad Khan, Mishaim Khan, Harshith Thyagaturu, Nimra Shafi, Fnu Muhibullah, Kainat Kanwal, Khuram Irshad, Gregg C Fonarow, Yasar Sattar","doi":"10.1080/14779072.2026.2650529","DOIUrl":"10.1080/14779072.2026.2650529","url":null,"abstract":"Introduction: Biodegradable devices for transcatheter patent foramen ovale (PFO) closure offer an alternative to nitinol occluders by enabling effective closure without leaving a permanent implant. Metallic devices have excellent success but can cause inflammation, device-related complications, and challenges for future transseptal procedures. Biodegradable platforms, including collagen matrices and fully polymeric frames, aim to provide early stability followed by controlled resorption and tissue replacement.Areas covered: Preclinical studies show rapid endothelialization, favorable biocompatibility, and organized tissue ingrowth during degradation. Early human experience with BioSTAR, Mallow, ABSNow, and Carag devices demonstrates high procedural success, good short-term occlusion, and imaging evidence of resorption. Recent multicenter studies and a randomized trial report non-inferior closure rates compared with nitinol devices and near-complete resorption within 12 to 24 months. Device-related issues such as transient thrombus, residual shunting, and structural limitations indicate the need for tailored antithrombotic therapy and careful follow-up.Expert opinion: Biodegradable occluders may be valuable for younger patients or those who may need future left-sided interventions. Early results are promising, but long-term clinical data are limited, and definitive evidence of reduced late complications or better stroke-prevention outcomes is still lacking. Further optimization of materials, standardized imaging endpoints, and long-term comparative studies remain priorities.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"353-363"},"PeriodicalIF":2.1,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147722124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0